Basecamp Research has integrated its EDEN antibiotic design and vaccine target prediction models with Claude, allowing researchers to design antibiotics and prioritize vaccine targets through Claude Science and related interfaces.

EDEN’s vaccine design model identifies proteins likely to provoke protective immune responses and, when paired with Claude, can prioritize targets from a pathogen’s genetic sequence in a single conversation, potentially saving weeks of research per pathogen.

Basecamp Research plans to scale BaseData 100-fold in two years through the Trillion Gene Atlas partnership with Anthropic, NVIDIA, PacBio, and Ultima Genomics to support AI-driven drug discovery.

BaseData, the training foundation for EDEN, is built from Basecamp Research’s extensive global data collection—over a million species and more than ten billion new genes—enabling broad applicability across pathogens.

The EDEN project emphasizes data provenance and equitable benefit-sharing, with samples obtained under informed consent and country/community-specific permits to ensure revenues support source communities.

In a UPenn-led collaboration, EDEN-designed antibiotic peptides showed activity against WHO priority pathogens in lab tests, and EDEN-7 reduced disease in mice infected with multidrug-resistant Acinetobacter baumannii without further optimization.

Basecamp Research frames EDEN as part of a broader push to tackle antimicrobial resistance and vaccine development as critical public health challenges, underscoring potential global health impact.

The collaboration enables users to move from target identification to a shortlist of high-performing antibiotic or vaccine candidates via a conversational interface, trimming design time to minutes.